Dr. Sun is the Vice President at Tasly Group, and the CEO of Tasly Pharmaceuticals, Inc. of USA. Since joined Tasly in 2006, he has been focusing on innovative drug developments, research activity managements, and international R&D collaborations. Dr. Sun created several new drug innovation management models, such as the “reverse discovery” model, “labeling first” process, and “integrative development” SOP and thus far has led his team obtained 22 NDA approvals from 32 countries, established 7 international R&D Joint Ventures, and achieved 28 worldwide business deals worth $2 billion with those very top pharmaceuticals firms such as Transgene (France), Pharnext (France), Bayer (German). The most significant R&D activity of Dr. Sun is that he completed the historically worldwide first and only global phase III clinical development of a multi-herbal drug products under the US FDA regulations aimed for an NDA approval next year, which will generate significant interest in the biomedical space, and paves a new route for pharmaceutical R&D for complicated unmet medical needs. Dr. Sun is also serving as a full professor at Tianjin University of China, and Special Professor at University of Nottingham of UK, and Deputy Director at Center for TCM Research of Columbia University of NY, with 100+ publications in peer-reviewed medical and pharmaceutical journals.